Skip to main content

Orabloc Disease Interactions

There are 8 disease interactions with Orabloc (articaine / epinephrine).

Major

Articaine (applies to Orabloc) allergies

Major Potential Hazard, Moderate plausibility. Applicable conditions: Asthma

Products with articaine (usually in combination with epinephrine) contain sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown. Sulfite sensitivity is seen more frequently in asthmatic than in non- asthmatic people. Articaine products are contraindicated in patients who are hypersensitive to sulfites.

Switch to professional interaction data

Major

Sympathomimetics (applies to Orabloc) cardiovascular disease

Major Potential Hazard, High plausibility. Applicable conditions: Hyperthyroidism, Pheochromocytoma

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

Switch to professional interaction data

Major

Sympathomimetics (applies to Orabloc) dehydration

Major Potential Hazard, High plausibility.

The use of sympathomimetic amines has been infrequently associated with significant hypotension especially in dehydrated patients secondary to the drug's beta-2 mediated vasodilation. Hypovolemia should be corrected, if possible, before administering sympathomimetic amines. Blood pressure and ECG should be monitored at regular intervals. Monitoring of cardiac output and pulmonary wedge pressure may also be desired.

Switch to professional interaction data

Moderate

Articaine (applies to Orabloc) liver/renal

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

No studies have been performed in patients with renal or liver impairment. Exercise caution when using products containing articaine and epinephrine in patients with severe liver or renal disease.

Switch to professional interaction data

Moderate

Articaine (applies to Orabloc) methemoglobinemia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: G-6-PD Deficiency, Heart Disease, Pulmonary Impairment

Cases of methemoglobinemia have been reported in association with local anesthetic use such as articaine. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. Caution is advised if used in these patients.

Switch to professional interaction data

Moderate

Epinephrine (applies to Orabloc) parkinson's disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Parkinsonism, Neurologic Disorder

Epinephrine should be administered with caution to patients with Parkinson's disease as these patients may experience psychomotor agitation or notice a temporary worsening of symptoms.

Switch to professional interaction data

Moderate

Sympathomimetics (applies to Orabloc) acidosis

Moderate Potential Hazard, High plausibility.

Acidosis, hypoxia, and hypercapnia may reduce the effectiveness of sympathomimetic amines in raising blood pressure. These conditions should be corrected before initiating therapy with sympathomimetic amines, if possible. Monitoring the patients acid-base balance, carbon dioxide levels, and oxygen saturation is recommended.

Switch to professional interaction data

Moderate

Sympathomimetics (applies to Orabloc) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Sympathomimetic agents may cause increases in blood glucose concentrations. These effects are usually transient and slight but may be significant with dosages higher than those normally recommended. Therapy with sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate.

Switch to professional interaction data

Orabloc drug interactions

There are 334 drug interactions with Orabloc (articaine / epinephrine).

Orabloc alcohol/food interactions

There is 1 alcohol/food interaction with Orabloc (articaine / epinephrine).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.